Solini, Anna http://orcid.org/0000-0002-7855-8253
Tricò, Domenico http://orcid.org/0000-0002-7633-1346
Del Prato, Stefano http://orcid.org/0000-0002-5388-0270
Funding for this research was provided by:
Università di Pisa
Article History
Received: 4 May 2023
Accepted: 22 June 2023
First Online: 5 August 2023
Authors’ relationships and activities
: AS has received research grants to the institution from Sankyo and Sanofi; has served as an advisor for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; and has received fees for speaking from Sanofi, Bayer, Boehringer Ingelheim, Novo Nordisk and Sankyo. DT has served as an advisor for Amarin; and has received fees for speaking from AstraZeneca, Eli Lilly & Co. and Novo Nordisk. SDP has served as president of EASD/European Foundation for the Study of Diabetes (EFSD) (2020–2022); has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has served as advisor for Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., Novo Nordisk, Sanofi and Sun Pharmaceuticals; and has received fees for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Merck Sharpe & Dohme and Novo Nordisk. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved this version to be published.